EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma

Matteo Mureddu, Serena Pelusi, Oveis Jamialahmadi, Marijana Vujkovic, Lorenzo Miano, Hadi Eidgah Torghabehei, Luisa Ronzoni, Francesco Malvestiti, Marco Saracino, Giulia Periti, Vittoria Moretti, Craig C Teerlink und 23 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci201762 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Matteo Mureddu und 34 weiteren Autor:innen. Beteiligte Einrichtung: Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Fatty Liver, Apolipoprotein B-100. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, Italian Ministry of Health, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Metabolic dysfunction–associated steatotic liver disease (MASLD) has a substantial inherited component. Rare variants in apolipoprotein B gene ( APOB ) have been implicated in susceptibility to liver steatosis, but their role in disease progression and outcomes is unclear. METHODS We investigated APOB rare variants in a case-control cohort of people with advanced MASLD versus healthy controls ( n = 510 and 261, respectively), a family-based study ( n = 43 and literature meta-analysis), the Million Veteran Program (MVP) cohort ( n = 94,885), and the UK Biobank (UKBB) ( n = 417,657). RESULTS In the clinical cohort, APOB variants were enriched in people with advanced MASLD (OR 13 . 8, 95% CI: 2 . 7–70 . 7, P = 0 . 002) and associated with lower circulating lipids, but higher MASLD activity and fibrosis ( P < 0 . 05). In the family study, APOB variants segregated with hepatic steatosis and fibrosis ( P < 0 . 05). Cross-ancestry meta-analysis of the study cohorts yielded pooled ORs for cirrhosis and hepatocellular carcinoma (HCC) of 1 . 82, 95% CI: 1 . 33–2 . 49 and 3 . 53, 95% CI: 2 . 09–5 . 98, respectively. Variants affecting specifically ApoB100 had a 3-fold greater effect on hepatic lipid metabolism compared with those impairing also ApoB48 and were specifically protective against coronary artery disease ( P < 0 . 05). The variants affected cirrhosis risk similarly, but ApoB48/100 had a larger effect on HCC ( P < 0 . 05). CONCLUSIONS Rare APOB variants predispose individuals to advanced MASLD and HCC, with distinct contributions from disrupted VLDL and chylomicrons secretion. These findings highlight the interplay between hepatic and intestinal lipid handling, suggesting that APOB genotyping may enhance MASLD risk stratification and patient identification. FUNDING European Union, Italian Ministry of Health, Swedish Research Council, Veterans Health Administration, NIH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularFatty LiverApolipoprotein B-100Apolipoproteins BHumansFemaleGenetic Predisposition to DiseaseMaleMiddle AgedAgedCase-Control Studies

Stichwörter der Autor:innen

Genetic risk factorsGeneticsHepatologyLipoproteinsLiver cancer

Substanzen

APOB protein, humanApolipoprotein B-100Apolipoproteins B

Autor:innen und Institutionen

  • Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy.
  • Precision Medicine and Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Scientific Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.

Förderung

  • BLRD VA
  • Italian Ministry of Health
  • Horizon 2020 Framework Programme
  • Italian Ministry of Research

Zitieren

APA

Mureddu, M., Pelusi, S., Jamialahmadi, O., Vujkovic, M., Miano, L., Eidgah Torghabehei, H., Ronzoni, L., Malvestiti, F., Saracino, M., Periti, G., Moretti, V., Teerlink, C. C., Lynch, J. A., Tsao, P. S., Johnson, J. P., La Mura, V., Dilena, R., Alqahtani, S. A., Cherubini, A., …, & Valenti, L. V. (2026). Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci201762

Vancouver

Mureddu M, Pelusi S, Jamialahmadi O, Vujkovic M, Miano L, Eidgah Torghabehei H, et al. Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma. Journal of Clinical Investigation. 2026. doi:10.1172/jci201762

BibTeX
@article{Mureddu2026,
  author = {Mureddu, Matteo and Pelusi, Serena and Jamialahmadi, Oveis and Vujkovic, Marijana and Miano, Lorenzo and Eidgah Torghabehei, Hadi and Ronzoni, Luisa and Malvestiti, Francesco and Saracino, Marco and Periti, Giulia and Moretti, Vittoria and Teerlink, Craig C and Lynch, Julie A and Tsao, Philip S and Johnson, Josephine P and La Mura, Vincenzo and Dilena, Robertino and Alqahtani, Saleh A and Cherubini, Alessandro and EPIDEMIC Study Investigators, EPIDEMIC Study Investigators and Million Veteran Program, Million Veteran Program and Russo, Francesco Paolo and D'Ambrosio, Roberta and Fraquelli, Mirella and Petta, Salvatore and Miele, Luca and Vespasiani-Gentilucci, Umberto and Bugianesi, Elisabetta and Mancina, Rosellina M and Parini, Paolo and Prati, Daniele and Chang, Kyong-Mi and Schneider, Carolin V and Romeo, Stefano and Valenti, Luca Vc},
  title = {Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci201762}
}
Kostenlos starten →